Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus

被引：0
作者：
Chen, Henry W. [1 ]
Liu, Jialiang [2 ]
Yang, Donghan M. [2 ]
Xie, Yang [2 ]
Peterson, Eric D. [3 ]
Navar, Ann Marie [3 ]
Chong, Benjamin F. [1 ]
机构：
[1] Univ Texas, Dept Dermatol, Southwestern Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 78712 USA
[2] Univ Texas Southwestern Med Ctr, Quantitat Biomed Res Ctr, Peter ODonnell Jr Sch Publ Hlth, Dallas, TX USA
[3] Univ Texas, Dept Internal Med, Div Cardiol, Southwestern Med Ctr, Dallas, TX USA
来源：
JAMA DERMATOLOGY | 2025年 / 161卷 / 02期
基金：
美国国家卫生研究院;
关键词：
MYOCARDIAL-INFARCTION; PSORIATIC-ARTHRITIS; GENERAL-POPULATION; RISK; SMOKING; CANCER; ALPHA;
D O I：
10.1001/jamadermatol.2024.4991
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
IMPORTANCE Autoimmune diseases such as systemic lupus erythematosus (SLE) and psoriasis have been previously associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Whether similar increased ASCVD risk is seen with cutaneous lupus erythematosus (CLE) remains unclear. OBJECTIVE To evaluate the incidence and prevalence of ASCVD among those with CLE, SLE, and psoriasis compared with a disease-free control group. DESIGN, SETTING, AND PARTICIPANTS This retrospective, matched longitudinal cohort study used data from January 2018 to December 2020 in the IBM MarketScan Commercial Claims and Encounters Database. The control population included individuals free of CLE, SLE, and psoriasis, matched 10:1 with the CLE population on age, sex, insurance type, and enrollment duration. Data were analyzed from September 2022 to April 2024. MAIN OUTCOMES AND MEASURES Prevalent ASCVD was defined as coronary artery disease, prior myocardial infarction, or cerebrovascular accident. Incident ASCVD was assessed through the number of hospitalization events through the end of follow-up (up to 3 years) in each group. Multivariable logistic regression and Cox proportional hazards models were performed to compare the prevalence and incidence of ASCVD between exposure groups, adjusting for age, sex, and cardiovascular risk factors. RESULTS A total of 8138 persons with CLE (median [IQR] age, 49 [40-47] years; 6618 [81%] female), 24675 with SLE (median [IQR] age, 46 [36-54] years; 22432 [91%] female), 192577 persons with psoriasis (median [IQR] age, 48 [36-56] years; 106 631 [55%] female), and 81380 control individuals (49 [40-57] years; 66180 [81%] female) were identified. In multivariable analysis, the odds of ASCVD were higher than control for CLE (odds ratio [OR], 1.72 [95% CI, 1.45-2.02]; P < .001) and SLE (OR, 2.41 [95% CI, 2.14-2.70]; P < .001), but not psoriasis (OR, 1.03 [95% CI, 0.95-1.11]; P = .48). At median 3 years follow-up, incidence rates of ASCVD were highest for SLE (24.8 [95% CI, 23.3-26.4] per 1000 person-years), followed by CLE (15.2 [95% CI, 13.1-17.7] per 1000 person-years), psoriasis (14.0 [95% CI, 13.5-14.4] per 1000 person-years), and then controls (10.3 [95% CI, 9.77-10.94] per 1000 person-years). In multivariable Cox proportional regression modeling with the control group as a reference group, the highest risk of incident ASCVD was in those with SLE (hazard ratio [HR], 2.23 [95% CI, 2.05-2.43]; P < .001), followed by CLE (HR, 1.32 [95% CI, 1.13-1.55]; P < .001), and psoriasis (HR, 1.06 [95% CI, 0.99-1.13]; P = .09). CONCLUSIONS AND RELEVANCE In this retrospective matched longitudinal cohort study, CLE was associated with an increased risk for ASCVD, similar to the risk in SLE but higher than the risk in psoriasis. The role of comorbidities that augment ASCVD risk like smoking status should be further investigated. Clinicians treating patients with CLE can consider them at increased ASCVD risk and institute appropriate screening tests.
引用
收藏
页码：175 / 182
页数：8
相关论文
共 43 条
  • [1] Fava A., Petri M., Systemic lupus erythematosus: diagnosis and clinical management, J Autoimmun, 96, pp. 1-13, (2019)
  • [2] Churton S., Brown L., Shin T.M., Korman N.J., Does treatment of psoriasis reduce the risk of cardiovascular disease?, Drugs, 74, 2, pp. 169-182, (2014)
  • [3] Yang Z.S., Lin N.N., Li L., Li Y., The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis, Clin Rev Allergy Immunol, 51, 2, pp. 240-247, (2016)
  • [4] Hak A.E., Karlson E.W., Feskanich D., Stampfer M.J., Costenbader K.H., Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study, Arthritis Rheum, 61, 10, pp. 1396-1402, (2009)
  • [5] Avina-Zubieta J.A., To F., Vostretsova K., De Vera M., Sayre E.C., Esdaile J.M., Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study, Arthritis Care Res (Hoboken), 69, 6, pp. 849-856, (2017)
  • [6] Gilliam J.N., Sontheimer R.D., Distinctive cutaneous subsets in the spectrum of lupus erythematosus, J Am Acad Dermatol, 4, 4, pp. 471-475, (1981)
  • [7] Akarsu S., Ozbagcivan O., Semiz F., Aktan S., High prevalence of metabolic syndrome in patients with discoid lupus erythematosus: a cross-sectional, case-control study, J Immunol Res, 2017, (2017)
  • [8] Guembe M.J., Fernandez-Lazaro C.I., Sayon-Orea C., Toledo E., Moreno-Iribas C., Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort, Cardiovasc Diabetol, 19, 1, (2020)
  • [9] Westermann R., Zobbe K., Cordtz R., Haugaard J.H., Dreyer L., Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: a Danish nationwide cohort study, Lupus, 30, 5, pp. 752-761, (2021)
  • [10] Gronhagen C.M., Fored C.M., Granath F., Nyberg F., Increased risk of cancer among 3663 patients with cutaneous lupus erythematosus: a Swedish nationwide cohort study, Br J Dermatol, 166, 5, pp. 1053-1059, (2012)
12345